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Urinary recovery and kinetics of sulphamethoxazole and its
metabolites in HIV-seropositive patients and healthy
volunteers after a single oral dose of sulphamethoxazole
ANDRÉ J. A. M. VAN DER V EN 1, TOM B. VREE2, ELEONORA W. J. VAN EWIJK-BENEKEN KOLMER 
PETER P. KOOPM ANS' & JOS W. M. VAN DER MEER1
Department or General Internal Medicine, Division of Internal Medicine and Department o f Clinical Pharmacy, 
Academic Hospital, Nijmegen St Radboud, PO Box 9101, 6500 HB Nijmegen, The Netherlands
1 The urinary excretion of sulphamethoxazole and its metabolites was compared 
between healthy volunteers and HIV-seropositive patients in order to get a better 
understanding of why HIV séropositives are more predisposed to idiosyncratic 
toxicity of sulphonamides.
2 A single 800 mg oral dose of sulphamethoxazole was administered to seven 
healthy volunteers and seven asymptomatic HIV séropositives without previous 
use of sulphonamides.
3 Urine was collected for 4 days and drug analysis was by h.p.l.c.
4 No difference was observed between seropositive and seronegative individuals in 
the urinary recovery of sulphamethoxazole, A^4-acetyl-, 5-hydroxy-, V4-acetyl-5- 
hydroxy-sulphamethoxazole and the AT-glucuronide conjugate. However the 
recovery of the hydroxylamine metabolite of sulphamethoxazole was significantly 
lower in the HIV séropositives (0.50 ± 0.51 vs 2.23 ± 0.85%; 95% Cl on the dif­
ference, -0 .90  to -2.55; P  = 0.0006).
5 Sulphamethoxazole hydroxylamine may be a factor in the susceptibility of HIV 
infected individuals to sulphonamides.
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Figure 1 Metabolism of sulphamethoxazole.
HIV-seropositive individuals in order to obtain more Sampling procedures
insight into the reasons why HIV séropositives are 
more predisposed to sulphonamide toxicity. B lood samples were only from the
M ethods
Subjects
volunteers while urine samples were collected from 
both  healthy volunteers and séropositives. Blood 
sam ples were obtained by fingertip puncture at 1, 2 ,
4, 6 , 8 , 10, 12, 24, 32, 36, and 48 h after drug admin 
istration. Plasma was separated immediately by cen­
trifugation and stored at -2 0 °  C until analysis. Urine 
was collected over 96 h and three 5 ml aliquots were
Seven healthy volunteers (4 M, 3 F) aged between 23 stored immediately at -2 0 °  C until analysis.
and 50 years (mean 34 years) and seven HIV-sero- Sam ple treatment and drug analysis has been de
positive volunteers participated in the study after scribed in detail elsewhere [18]. 
approval o f the E thics Com m ittee o f Academ ic H os­
pital, Nijmegen. Routine biochemical assessm ents D ata  analysis  
(including liver function) were within normal limits
in all participants. The HIV-seropositive individuals C urve fitting of the plasma concentration- and renal
(6  M, 1 F) were aged betw een 31 and 53 years (mean excretion rate-time curves was carried out using a one
39 years), were all asymptomatic, CDC class II, had a 
mean CD 4 count o f 294 ± 111/mm3 (range 140-480/
m m 3) and were w ithout previous sulphonam ide treat- lated using the M edi-ware® com puter program [23].
com partm ent model with first order drug absorption
( r 2 < 0.98) and pharmacokinetic
ment after seroconversion. The following parameters for V4-SM X were calcu-
W ritten inform ed consent was obtained from all lated from  the renal excretion rate-time profiles: elim- 
participants. An 800 mg dose o f sulpham ethoxazole ination half-life (fi/2,y), lag time (t\a„), time at which
was adm inistered orally in two gelatine capsules after m axim um  excretion occurs (imax), mean 
an overnight fast. Two volunteers participated twice tim e (MRT = VSS/C L  + \ /ka + f|ag), maximal renal 
in the study in order to determ ine the reproducibility. excretion rate (Umax) and area under renal excretion
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Statistics
95%  confidence intervals on the differences of the 
m eans for unpaired (or paired when appropriate) 
observations were determined.
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Table 1 Urinary recovery of sulphamethoxazole and its metabolites in seven healthy volunteers 
and seven HIV seropositives (expressed as percentage of the dose of sulphamethoxazole) after an 
oral dose of 800 mg sulphamethoxazole. Mean values ± s.d. and 95% confidence intervals cm 
differences between the mean values are given
pi... . ‘ i y y p . t e f f r r i r ' i I I î i V' ‘' V. r  •’ *• . i_
H IV  seropositives
(n = 7)
Healthy vo lu n tec> r\\
fn = 7) 95%  C l P
¿V4-SMX 50.27 ±8.63 43.21 ± 6.25 -1 .7 2  to 15.84
fí'iJ f ' « y. !>.».;>• ir*' - ............. .. - '■> r-
0.1 1
SMX 12.66 ±5.02 14.64 ± 3.80 -“7.18 to 3 . 20 0.42
N 1 -gluc-SMX 12.68 ±2.68 9.66 ± 3 . 00 -0 .2 9  to 6.33 0.07
N4-50H-SMX 5.50 ± 1.59 5.20 ± 1.07 -1 .28  to 1.88 0.68
50H-SMX 3.64 ± 1.94 2.70 ± 1.19 -2 .8 2  to 0.94 0 ”*9
NOH-SMX 0.50 ±0.51 2.23 ± 0.85 -0 ,90  to *2,55 0,0006
Total 83.9 ± 6.23 78.25 ± 5.23 -1 «04 to 1235 0.09
i
yV4-acetylsulphamethoxazole (N4-SMX), sulphamethoxazole (SMX), AH-glucuronidc conjugate* 
(SMX-gluc), 7V4-aeety]-5-hydroxy-sulphamethoxazole (W4-50H-SMX), 5-hydroxyxulpham«,*th' 
oxazole (50H-SMX) and sulphamethoxazole hydroxylaniine (NOH-SMX).
Table 2 Pharmacokinetic parameters of /V4-acetylsulphi i/.ole in urine of HIV
seropositives and healthy volunteers after an oral dose of 800 mg sulphamethoxazole. Mean val
ues ± s.d. (inlax is median and range) are given as well as 95% 
differences between the mean values
Ì intervals (C l) on the
H IV  seropositives
(n = 7)
H ealthy vo lun teers
(n = 7)
inf. mjnrgitfWnwMit fci mini . .
95%  C l
' í l fay. i-J/,<«■ 1 -*'/j■ '-h ,*r
P
(h) 8.69 ±2.12 10.34 ± 1.42 “•3.74 to 0.46 0.11
0.69m^ux (1*) 7.48* (5.60-8.57) 6.56* (5.96-11.06) -2 .0 5  to 1.41
l^ng (h) 0.57 ± 0.48 0.34 ± 0.24 “ 0.22 to 0,67 0,29
MRT (h)
Umax (mg h“‘)
17.43 ±2.11 19.40 ± 2.85 —4.89 to 0,96 0,17
0.0423.28 ±6.16 17.16 ± 3.27 0.37 to 11.87
AUCU (mg) 478 ± 90 405 ± 5 3 “ 12.55 to 158.83 0.09
*•/„* = half-life, fmax = time at which maximum excretion occurs, »expressed as median (range). /it ,
= lag time, MRT = mean residence time, Umux = maximum renal excretion rate. * ^è n ti*  A
under renal excretion rate-time curve.
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Discussion
The formation and elimination of sulphamethoxazole 
and all its known metabolites in healthy volunteers 
and HIV-seropositive individuals were compared to 
understand better the predisposition of HIV sero­
positives to sulphonamide toxicity. Only the urinary 
recovery of sulphamethoxazole hydroxylamine dif­
fered between healthy volunteers and HIV-seroposi­
tive individuals. No difference was observed in 
urinary recovery of SMX, W4-SMX, SMX-gluc, N4- 
50H-SMX and 50H-SMX. The formation of the 
latter metabolite is, like NOH-SMX and probably N4- 
50H-SMX, catalysed by cytochrome P450 [20].
These findings suggest that there is no difference in
The reduced urinary recovery of the hydroxylamine 
metabolite may be explained by secondary meta­
bolism of an unstable compound that can be further 
oxidized to reactive metabolites [20]. This process is
prevented e.g. by glutathione. Glutathione protects 
cells from the toxicity of NOH-SMX largely by pre­
venting its further oxidation to reactive metabolites 
[20]. These results suggest that the formation of the 
hydroxylamine metabolite is similar in both groups 
but that only HIV seropositives further metabolize 
NOH-SMX. This could explain the increased fre­
quency of adverse reactions and the diminished 
recovery of NOH-SMX in this group of individuals.
The renal excretion rate-time profile of A/4-SMX 
was taken as the main parameter for comparison of 
the metabolic and kinetic behaviour of SMX in healthy 
volunteers and HIV seropositives. Although the 
maximum renal excretion rate (Umax) was different, 
other parameters like ?max, ilag, MRT and AUCU were 
not. It may therefore be concluded that the renal 
excretion of V4-SMX does not differ between 
seropositives and healthy volunteers.
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